EHA Library - The official digital education library of European Hematology Association (EHA)

Abstract

Abstract: P330

Type: Poster Presentation

Presentation during EHA22: On Friday, June 23, 2017 from 17:15 - 18:45

Location: Poster area (Hall 7)

Background

Multiple myeloma (MM) is generally considered an incurable disease, however advances in the treatment options for MM have been great in recent years. Recent studies on these new agents indicate an improvement in survival, nevertheless population-based studies have had contradicting findings, especially in the elderly patients.

Aims

The aim of the study was to evaluate the survival of all patients diagnosed with MM in Sweden in the years 1973 to 2013 and to relate the survival pattern to trends in treatment strategies.

Methods

Patients diagnosed with MM in the period from January 1, 1973 to December 31, 2013 were identified from the Swedish Cancer Registry. Information on sex, date of birth, date of diagnosis, and date of death was collected. Relative survival ratios (RSRs) were used to provide a measure of excess mortality of MM patients compared to a comparable group from the general population. RSRs with 95% confidence intervals (Cis) were found for 1-, 5-, and 10- years for 4 calendar periods; 1973-1982, 1983-1992, 1993-2002, and 2003-2013 and furthermore for 6 age categories at diagnosis (0-40, 41-50, 51-60, 61-70, 71-80 and >80). Short-term survival, as defined by RSR of less than 3 months, was also defined for all calendar periods.

Results

A total of 21,465 patients (54% males, median age at diagnosis 72 years) with MM were recorded in the time period. Overall, the 1- and 5- and 10- year RSRs improved in the whole period, with the greatest improvement in the two most recent calendar periods. The 1-year RSR increased significantly between all calendar periods (0.69, 0.74, 0.77 and 0.82, respectively). The 5-year RSR increased significantly between the two last calendar periods (0.28, 0.31, 0.33 and 0.41, respectively; Figure) as well as the 10-year RSR (0.10, 0.12, 0.14 and 0.20, respectively). Short-term survival increased significantly between the first two and last two calendar periods (the RSR were 0.83, 0.88, 0.89 and 0.93 respectively). Females had a lower excess mortality compared to males (excess mortality ratio 0.91).

Conclusion

In this population-based study, based on more than 21,000 MM patients diagnosed during more than a 40-year period, we showed that with an increased use of novel agents in MM patients, survival has improved significantly. This is especially prominent during the last 10 years.  Our findings are important, since new agents are approved based on clinical trials, where certain groups, such as older patients and patients with significant comorbidities are often excluded.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Treatment, Survival, Population, Multiple Myeloma

Abstract: P330

Type: Poster Presentation

Presentation during EHA22: On Friday, June 23, 2017 from 17:15 - 18:45

Location: Poster area (Hall 7)

Background

Multiple myeloma (MM) is generally considered an incurable disease, however advances in the treatment options for MM have been great in recent years. Recent studies on these new agents indicate an improvement in survival, nevertheless population-based studies have had contradicting findings, especially in the elderly patients.

Aims

The aim of the study was to evaluate the survival of all patients diagnosed with MM in Sweden in the years 1973 to 2013 and to relate the survival pattern to trends in treatment strategies.

Methods

Patients diagnosed with MM in the period from January 1, 1973 to December 31, 2013 were identified from the Swedish Cancer Registry. Information on sex, date of birth, date of diagnosis, and date of death was collected. Relative survival ratios (RSRs) were used to provide a measure of excess mortality of MM patients compared to a comparable group from the general population. RSRs with 95% confidence intervals (Cis) were found for 1-, 5-, and 10- years for 4 calendar periods; 1973-1982, 1983-1992, 1993-2002, and 2003-2013 and furthermore for 6 age categories at diagnosis (0-40, 41-50, 51-60, 61-70, 71-80 and >80). Short-term survival, as defined by RSR of less than 3 months, was also defined for all calendar periods.

Results

A total of 21,465 patients (54% males, median age at diagnosis 72 years) with MM were recorded in the time period. Overall, the 1- and 5- and 10- year RSRs improved in the whole period, with the greatest improvement in the two most recent calendar periods. The 1-year RSR increased significantly between all calendar periods (0.69, 0.74, 0.77 and 0.82, respectively). The 5-year RSR increased significantly between the two last calendar periods (0.28, 0.31, 0.33 and 0.41, respectively; Figure) as well as the 10-year RSR (0.10, 0.12, 0.14 and 0.20, respectively). Short-term survival increased significantly between the first two and last two calendar periods (the RSR were 0.83, 0.88, 0.89 and 0.93 respectively). Females had a lower excess mortality compared to males (excess mortality ratio 0.91).

Conclusion

In this population-based study, based on more than 21,000 MM patients diagnosed during more than a 40-year period, we showed that with an increased use of novel agents in MM patients, survival has improved significantly. This is especially prominent during the last 10 years.  Our findings are important, since new agents are approved based on clinical trials, where certain groups, such as older patients and patients with significant comorbidities are often excluded.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Treatment, Survival, Population, Multiple Myeloma

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies